82 results
Page 4 of 5
424B3
wfex4a27
15 Oct 18
Prospectus supplement
12:00am
424B5
r43xc06tvfuj
13 Sep 18
Prospectus supplement for primary offering
12:00am
6-K
EX-99.2
sg5fud6r
2 Aug 18
Current report (foreign)
4:03pm
6-K
EX-99.1
t3172y6vdrznat9
2 May 18
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
6:00am
6-K
EX-99.2
ot6zjs vjm7ycx
27 Apr 18
Galapagos reports first quarter 2018 results
12:00am
424B5
rkmre11z zdu7
18 Apr 17
Prospectus supplement for primary offering
12:00am
6-K
EX-3.1
g5sjqs7i nw9cnbrvxl5
18 Apr 17
Galapagos announces launch of proposed public offering
12:00am
424B5
ixz 9xywkh
17 Apr 17
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
ziwk0gqi b4uqwa
14 Jul 16
FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016
12:00am
20-F
g0zjcloy6p7n1org wt8
25 Mar 16
Annual report (foreign)
12:00am
20-F
EX-1.1
zsc 2ovh6s8z
25 Mar 16
Annual report (foreign)
12:00am
DRS/A
EX-10
m3vmt1 fj
4 Mar 15
Draft registration statement (amended)
12:00am
DRS/A
EX-10
ewyq0o94jlh7
4 Mar 15
Draft registration statement (amended)
12:00am
DRS
g1f92qdj
6 Feb 15
Draft registration statement
12:00am
DRS
EX-3
ao98q359qddhf1a
6 Feb 15
Draft registration statement
12:00am
DRS
EX-10
m8r4j 9r6cz1r
6 Feb 15
Draft registration statement
12:00am
DRS
EX-10
jok5lqrt42j e00e
6 Feb 15
Draft registration statement
12:00am